Fondaparinux: Pharmacology and clinical experience in cardiovascular medicine

Vincenzo Toschi, M. Lettino

Research output: Contribution to journalArticlepeer-review


Fondaparinux is a synthetic, five-saccharide chain, AT-dependent, anti-FXa agent. Studies showed that fondaparinux acts in prevention and treatment of venous thromboembolism and in ischemic heart disease, without significant bleeding risk. The drug inhibits thrombin generation, has long half-life and can be administered once-daily without laboratory monitoring. It may be used in HIT treatment.

Original languageEnglish
Pages (from-to)383-387
Number of pages5
JournalMini-Reviews in Medicinal Chemistry
Issue number4
Publication statusPublished - Apr 2007


  • Antithrombotic
  • Factor Xa inhibitor
  • Fondaparinux
  • Heparin
  • Low molecular weight heparin

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Chemistry(all)
  • Pharmacology


Dive into the research topics of 'Fondaparinux: Pharmacology and clinical experience in cardiovascular medicine'. Together they form a unique fingerprint.

Cite this